NasdaqGM:RYTMBiotechs
Rhythm Pharmaceuticals (RYTM) Stock Looks Pricey Following Strong IMCIVREE News
Rhythm Pharmaceuticals has delivered a very large 5 year return, yet its latest valuation checks and current trading multiples point to a stock that may now be pricing in a lot of optimism after the recent news on IMCIVREE and RM-718.
Rhythm Pharmaceuticals has returned about 7.99x over 5 years, which puts extra focus on whether recent gains are supported by fundamentals rather than momentum alone.
Regulatory progress for IMCIVREE and encouraging RM-718 trial data can support expectations...